Novo Nordisk A/S

CSE : NOVO.B


April 06, 2012 15:16 ET

Novo Nordisk A/S : Victoza® label in the US updated to include data showing superior efficacy when compared to Januvia®

Label update also includes FDA approval of combination therapy with basal insulin for the treatment of adults with type 2 diabetes

BAGSVAERD, DENMARK--(Marketwire - Apr 6, 2012) - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved to update the product label for Victoza® (liraglutide [rDNA] injection) to include data showing superior blood sugar control and weight reduction when compared to Januvia® (sitagliptin).

Company announcement 22 2012: http://hugin.info/2013/R/1600926/505405.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE

[HUG#1600926]

Contact Information